CN106213500A - A kind of Folium Nelumbinis compositions and application thereof - Google Patents
A kind of Folium Nelumbinis compositions and application thereof Download PDFInfo
- Publication number
- CN106213500A CN106213500A CN201610611570.3A CN201610611570A CN106213500A CN 106213500 A CN106213500 A CN 106213500A CN 201610611570 A CN201610611570 A CN 201610611570A CN 106213500 A CN106213500 A CN 106213500A
- Authority
- CN
- China
- Prior art keywords
- folium
- folium nelumbinis
- compositions
- group
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 239000000843 powder Substances 0.000 claims abstract description 48
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- 239000008280 blood Substances 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 235000013402 health food Nutrition 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 210000004185 liver Anatomy 0.000 claims description 29
- 240000000249 Morus alba Species 0.000 claims description 11
- 235000008708 Morus alba Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 21
- 239000008103 glucose Substances 0.000 abstract description 15
- 230000033228 biological regulation Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 230000012666 negative regulation of transcription by glucose Effects 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 230000003212 lipotrophic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 54
- 235000019197 fats Nutrition 0.000 description 32
- 241000700159 Rattus Species 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 27
- 239000000463 material Substances 0.000 description 21
- 240000002853 Nelumbo nucifera Species 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 19
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 18
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 18
- 238000011552 rat model Methods 0.000 description 17
- 210000003494 hepatocyte Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 235000013175 Crataegus laevigata Nutrition 0.000 description 14
- 230000002440 hepatic effect Effects 0.000 description 14
- 150000003626 triacylglycerols Chemical class 0.000 description 14
- 231100000240 steatosis hepatitis Toxicity 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 206010019708 Hepatic steatosis Diseases 0.000 description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 201000005577 familial hyperlipidemia Diseases 0.000 description 10
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 9
- 208000000501 Lipidoses Diseases 0.000 description 9
- 206010024585 Lipidosis Diseases 0.000 description 9
- 208000010706 fatty liver disease Diseases 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000003908 liver function Effects 0.000 description 8
- 102000000853 LDL receptors Human genes 0.000 description 6
- 108010001831 LDL receptors Proteins 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229930003944 flavone Natural products 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108700022737 rat Fat1 Proteins 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- -1 thiazole Alkane Chemical class 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 240000007930 Oxalis acetosella Species 0.000 description 2
- 235000008098 Oxalis acetosella Nutrition 0.000 description 2
- 235000010240 Paullinia pinnata Nutrition 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001610 euglycemic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000005161 hepatic lobe Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000020795 whole food diet Nutrition 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 101710142885 Arginine N-succinyltransferase Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical group C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 235000021506 Ipomoea Nutrition 0.000 description 1
- 241000207783 Ipomoea Species 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 101710105284 Sialin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- BPJYAXCTOHRFDQ-UHFFFAOYSA-L tetracopper;2,4,6-trioxido-1,3,5,2,4,6-trioxatriarsinane;diacetate Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].CC([O-])=O.CC([O-])=O.[O-][As]1O[As]([O-])O[As]([O-])O1.[O-][As]1O[As]([O-])O[As]([O-])O1 BPJYAXCTOHRFDQ-UHFFFAOYSA-L 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Folium Nelumbinis compositions and application thereof, described Folium Nelumbinis compositions is mixed to prepare by quality proportioning 81: 18: 18 by Folium Nelumbinis powder, powder of Folium Mori, Folium Ipomoeae powder, there is regulation blood fat, blood glucose and lipotropic effect, can be used for preparation regulation blood fat and prevention, improve and treat the food of non-alcoholic fatty liver disease, health food and medicine.The Folium Nelumbinis composition material of the present invention, from Chinese herbal medicines and food, is suitable to be eaten for a long time, it will bring good social benefit.
Description
Technical field
The present invention relates to raw processing food technical field, specifically, relate to a kind of containing Folium Nelumbinis powder, powder of Folium Mori and Folium Ipomoeae powder
Folium Nelumbinis compositions and preparation prevention, improve and treat hyperlipemia and the food of non-alcoholic fatty liver disease, health food
Or the application in terms of medicine.
Background technology
Fatty tissue contained by the liver of normal condition servant accounts for the 2%-4% of liver wet weights, and a variety of causes makes liver lactone
Fat pile up find more than 5% or in liver biopsy unit hepatocyte have more than 1/3 have a fat drop be referred to as fatty liver.Non-alcoholic
Fatty liver (Non-alcoholic fatty liver disease, NAFLD) refers to except ethanol and other clear and definite damage liver factors
Outer caused, with diffusivity hepatocyte Macrovesicular steatosis as principal character clinical pathology syndrome, accounts for the 80% of fatty liver.
Primary disease includes a series of lysis, and from simple fatty liver, non-alcoholic stellato-hepatitis to hepatic fibrosis, liver is hard
Change, finally can progress to hepatocarcinoma.At present, NAFLD worldwide falls ill and gradually increases, in China, along with economic bar
The improvement of part, living standards of the people improve constantly, and dietary habit and structure, working environment and mode have a very large change,
China's NAFLD sickness rate substantially increases (10.2%-17.3%), and has rejuvenation trend.This disease the most progressively develops into one
The public health problem that class is serious, is the second largest chronic hepatopathy after viral hepatitis, has had a strong impact on our people's
Physically and mentally healthy and social stability develops, and oneself becomes medical science and the social problem of whole world common concern to prevent and treat primary disease.
Along with constantly riseing of China's NAFLD sickness rate, the market demand of fatty liver medicine increases the most year by year.Mesh
Before, the related drugs of clinical treatment NAFLD includes that euglycemic agent, appetrol, lipid lowerers, antioxidant, hepatocyte protect
Protect agent, antibacterial agent etc..In recent years due to the untoward reaction report that appetrol are the most serious, 2011, the U.S., Europe
What alliance and Chinese food Drug Administration announced to forbid these slimming medicines successively continues to apply to clinic, the whole world at present
It is available for prescription without safely and effectively slimming medicine；Though many fat-reducing medicament such as Statins, fibrates etc. have obvious blood fat reducing
Effect, but increase liver fat content, promote lipid peroxidation, aggravate Liver fatty deposition；Euglycemic agent is (such as thiazole
Alkane diones TzDs) there is AMPK agonist effect and reduce FFA and the effect of inflammatory cytokine, but body weight can be induced to increase
And the untoward reaction such as Mt functional defect；Antioxidant such as Vit E, phosphatidylcholine, silymarin etc. can be by impact and livers
The expression of 26S Proteasome Structure and Function related gene, plays certain necrosis, apoptosis, antiinflammatory, fibrosis and work of promotion liver regeneration
With, but for want of appropriate design have the randomized, double-blind of certain sample size, placebo controlled trial, also difficulty assessment its respective face
Bed application status.Therefore find economy, effectively, the good product of few side effects, consumer compliance or medicine extremely urgent, become
Whole world hepatic disease medicine scholar's focus of attention.
Summary of the invention
It is an object of the invention to for the deficiencies in the prior art, it is provided that a kind of Folium Nelumbinis compositions and application thereof.In the present invention,
The combination of Folium Nelumbinis micropowder, Folium Mori micropowder and Folium Ipomoeae micropowder has the effect of Synergistic, three in function, mouthfeel
Combination can intestinal tract cleaning effectively, regulate blood lipid level, prevent and treat non-alcoholic fatty liver disease, Folium Nelumbinis and Folium Mori are medicine food simultaneously
Homology Chinese crude drug, Folium Ipomoeae is food, it is easy to be accepted.
It is an object of the invention to be achieved through the following technical solutions: a kind of Folium Nelumbinis compositions, it comprises Folium Nelumbinis powder, Mulberry
Ye Fen, Folium Ipomoeae powder, described Folium Nelumbinis powder, powder of Folium Mori, Folium Ipomoeae powder cross 800-1500 mesh sieve, by quality proportioning 8-1: 1-8: 1-8
Mixing.
Further, described Folium Nelumbinis powder, powder of Folium Mori, the quality proportioning of Folium Ipomoeae powder are preferably 8: 1: 1.
Described in a kind of claim 1, Folium Nelumbinis compositions regulates blood fat and prevention in preparation, improves and treat non-alcoholic fat
Application in the food of fat liver, health food and medicine.
Further, described Folium Nelumbinis compositions mass content in food, health food and medicine is 1-100%.
Beneficial effects of the present invention is as follows: for existing improvement or treatment hyperlipidemia, the fraud of non-alcoholic fatty liver disease product
End, the invention provides a kind of Folium Nelumbinis compositions, in described Folium Nelumbinis compositions, comprises the Folium Nelumbinis powder of certain content, powder of Folium Mori
With Folium Ipomoeae powder, can directly take after mixing it with water.This compositions is the combination of integration of edible and medicinal herbs Chinese crude drug and wholefood, has regulation
Abnormal blood fat and prevent and treat the effect of non-ethanol fatty liver, superfines eats form, and its effect is significantly higher than and commonly brews drink
Tea.
Pharmacology (animal) research confirms, Folium Nelumbinis compositions provided by the present invention is (with Folium Nelumbinis, Folium Mori and Folium Ipomoeae 8:1:1
Mixing smash into 800-1500 mesh as a example by) have blood fat reducing, preventing and treating non-alcoholic fatty liver disease effect.Give this comparative compositions
Rat model serum total cholesterol (TC), serum triglycerides (TG), alanine aminotransferase (ALT) level can be made to drop respectively
Low by 31.6%, 33.6%, 29.5%, simultaneously HDL-C (HDL-C) content raise 22.0%.Said composition is also
Liver index (declining 28.2%) can be significantly reduced, improve liver lipids infiltration and inflammatory reaction.
Folium Nelumbinis compositions of the present invention is made up of integration of edible and medicinal herbs Chinese crude drug and wholefood superfines, has safety good,
Availability is high, and effect is notable.
Folium Nelumbinis compositions of the present invention can be suitable to life-time service as bread and cheese, health food；Also medicine can be applied to by compatibility
Product are developed, it will bring good social benefit.
Accompanying drawing explanation
Fig. 1 is Folium Nelumbinis, Folium Mori and the Folium Nelumbinis compositions action diagram to NAFLD liver tissues of rats pathological change, in figure, (a)
For normal control figure, (b) is model comparison figure, and (c) is positive control figure, and (d) is the action diagram of Folium Nelumbinis, and (e) is the work of Folium Mori
With figure, (f) is the action diagram of Folium Nelumbinis and Folium Ipomoeae, and (g) is the action diagram of Folium Nelumbinis and Folium Mori, and (h) is the effect of Folium Nelumbinis compositions
Figure.
Fig. 2 is Folium Nelumbinis, Folium Mori and the effect to NAFLD rat hepatocytes lipidosis of the Folium Nelumbinis compositions, and in figure, (a) is
Normal control figure, (b) is model comparison figure, and (c) is positive control figure, and (d) is the action diagram of Folium Nelumbinis, and (e) is the effect of Folium Mori
Figure, (f) is the action diagram of Folium Nelumbinis and Folium Ipomoeae, and (g) is the action diagram of Folium Nelumbinis and Folium Mori, and (h) is the action diagram of Folium Nelumbinis compositions.
Detailed description of the invention
Folium Nelumbinis is the leaf of nymphaeaceae plant lotus (N.nucifera Gaertn), for " medicine-food two-purpose " Chinese crude drug, bitter and puckery flavor,
Micro-salty, property is pungent cool, containing alkaloids compositions such as the flavones ingredients such as Quercetin, nuciferine, miltanthins；There is clearing away summer-heat profit
The effects such as wet, yang invigorating dissipates, hemostasis by removing blood stasis.Lotus flavone is the scavenger of most of oxygen-derived free radicals, can improve superoxides
The vigor of dismutase (SOD), reduces malondialdehyde (MDA) and the life of OxLDL ELISA (OX-LDL)
Become；Lotus leaf alkaloid has the effects such as lowering blood-fat and reducing weight；Folium Nelumbinis preserved material and decoct have reduce internal heat antipyretic, expand blood vessel, blood pressure lowering make
With, it is fat-reducing good medicine；Though its effect is got instant result not as medicine, but has no side effect, to hypertension, hyperlipidemia, high gallbladder admittedly
Alcohol " three high " personage, friend person in middle and old age and the hope slender Ms that keeps good figure is optimal selection.
Folium Mori are the dried leaves of moraceae plants Mulberry (Morus alba L.), are all " medicine-food two-purpose " Chinese crude drug, cold in nature, taste
Sweetness and bitterness, has the effects such as dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, liver heat removing item, for one of clinical conventional Chinese medicine.Shennong's Herbal claims Mulberry
Leaf is " mulberry leaf ", have the good reputation of " Radix Ginseng is vulcanized, and Folium Mori are mended clearly ", is that health ministry confirms " integration of edible and medicinal herbs " plant,
Listed in " one of mankind's 21 century ten big health food " by international food health organization, become the green new food source of the mankind.Folium Mori
Rich in 17 kinds of aminoacid of human body, crude protein, crude fat and flavones ingredient；Modern pharmacological research proves, Folium Mori have blood sugar lowering,
The multiple pharmacologically actives such as blood fat reducing, blood pressure lowering and antiinflammatory, can be used for the auxiliary treatment of hyperglycemia, hyperlipemia, fatty liver etc..Mulberry
Alkaloid specific to leaf--1-DNJ (DNJ), can hinder at the little enteral direct action breaks sugar by enzyme
The sugar of picked-up, the decomposition of starch, effectively suppress steeply rising of blood glucose value after meal.Folium Mori effect for reducing blood fat is in recent years except fall
Another important research focus outside sugar effect.Studies have reported that, Folium Mori and flavones in mulberry leaves can effectively reduce hyperlipemia mould
Type animal serum TC, TG, LDL-C content, increasing serum SOD activity, the generation of suppression peroxide, be a kind of extraordinary can
It is applied to prevent and treat the natural health care raw material of non-alcoholic fatty liver disease.
Folium Ipomoeae, also known as Folium Ipomoea, Radix Pachyrhizi Erosi leaf, is the new varieties selecting edible young stem and leaf through artificial selection.Ipomoea batatas Lam.
Tender leaf delicate mouthfeel, fragrant odour, it is described as " vegetable queen ".Folium Ipomoeae sweet-puckery flavor, slightly cool in nature, replenishing QI to invigorate the spleen.Modern nutrition
Research finds, Folium Ipomoeae is rich in carotene, vitamin C, calcium, phosphorus, ferrum and essential amino acids, but oxalic acid content is less；Its institute is rich
The fiber contained can promote food operating in gastrointestinal, has the effect of intestinal tract cleaning；Contained flavone compound has antioxygen
Change, improve the various health-care such as human disease resistance, slow down aging, antiinflammatory anti-cancer；In Folium Ipomoeae containing substantial amounts of liquid eggs in vain,
The lipidosis of cardiovascular system can be prevented, keep the prevention of arterial vascular elasticity, beneficially coronary heart disease.
In China, Folium Nelumbinis and Folium Mori all have the custom doing tea-drinking, and Folium Ipomoeae is used for keeping healthy frequently as dish.Folium Nelumbinis subtracts
Fertile, reduce internal heat antipyretic, fall three-hypers, white mulberry leaf blood-sugar-reducing, diuresis, fat-reducing, Folium Ipomoeae antioxidation, intestinal tract cleaning, anti-lipidosis；Lotus
Leaf, Folium Mori are integration of edible and medicinal herbs Chinese crude drug, and Folium Ipomoeae is food, Folium Nelumbinis, Folium Mori and Folium Ipomoeae superfines compatibility are applied, make three
Person's effect is complementary, thus is formed and have regulation blood fat and prevent and treat the compositions of non-ethanol fatty liver, can direct Instant Drinks or be used for protecting
Health food, the preparation of medicine.The exploitation of said composition the most effectively enhances effect of Folium Nelumbinis, Folium Mori and Folium Ipomoeae, improves
Resource utilization, can meet again the health care demand of modern.
The Folium Nelumbinis compositions that the present invention provides, comprises Folium Nelumbinis powder, powder of Folium Mori, Folium Ipomoeae powder, and Folium Nelumbinis powder, powder of Folium Mori, kind
The mass percent of potato leaf powder is 8-1: 1-8: 1-8.
Be different from tradition soak take tea drink or use modern provide technique to extract after granulation etc. take after mixing it with water, directly by lotus
Leaf, Folium Mori and Folium Ipomoeae are freeze-dried and combination pulverizing process makes natural superfine powder composition, can at utmost retain
The Folium Nelumbinis such as flavone, 1-DNJ, liquid eggs are white, chlorophyll, dietary fiber, aminoacid, Folium Mori and each contained by Folium Ipomoeae
Active component efficient absorption utilize, thus preferably play regulation blood fat, the purpose of preventing and treating non-alcoholic fatty liver disease.Lotus
Leaf, Folium Mori and Folium Ipomoeae micropowder, color and luster is dark green, abnormal smells from the patient delicate fragrance, Instant Drinks, edible and add extremely convenient, nutrition as dispensing
Ingredient draws is fast, and delicate mouthfeel, long-term taking also has good compliance.
The present invention further provides one by Folium Nelumbinis, Folium Mori and Folium Ipomoeae micropowder compositions various food, guarantor
Application in the dosage form of health food or medicine, such as solid beverage, granule, tablet, capsule, applied widely, the suitability is strong.
The present invention further provides a kind of freeze-dried and combines pulverizing process (crossing 800-1500 mesh sieve) and makes
Folium Nelumbinis, Folium Mori and Folium Ipomoeae micropowder compositions, can preferably absorb and give full play to the mutual of contained nutritional labeling
The effect work in coordination with, mutually promoted so that it is intestinal tract cleaning, regulate blood fat, effect of preventing and treating non-ethanol fatty liver is strengthened, three
In conjunction with, in prevention with improve hyperlipemia and non-alcoholic fatty liver disease application aspect plays beyond thought effect, have higher
Edibility and health care diseases prevention be worth.
Below by following example, the invention will be further described, and it will assist in and understands the present invention, but does not limit
Present disclosure processed.
Embodiment 1: Folium Nelumbinis compositions causes the Effect study of non-alcoholic fatty liver disease to high lipid food
1, experiment material
1.1, animal: male SD rat, body weight 200 ± 20g, Zhejiang Academy of Medical Sciences Experimental Animal Center provide,
The quality certification: 0012051, credit number SCXK (Zhejiang) 2014-0001.In room temperature 23 ± 2 DEG C, relative humidity 50%～70% is raised
Supporting, free diet is drunk water.
1.2, tested material: the lyophilization to pulverize the Folium Nelumbinis of 800-1000 mesh sieve, powder of Folium Mori appropriate of learning from else's experience, adds pure respectively
Water is configured to suspension, obtains Folium Nelumbinis tested material and Folium Mori tested material；Separately take Folium Nelumbinis, Folium Ipomoeae and Folium Nelumbinis, Mulberry respectively in 8:2 ratio
Leaf, mixing, add pure water and be configured to suspension, obtain lotus kind tested material and Hawthorne tested material；Take Folium Nelumbinis, Folium Mori and Folium Ipomoeae powder by 8:
1:1 mixes, and adds pure water and is configured to suspension, obtains Folium Nelumbinis compositions tested material.
2, experimental technique
2.1, being grouped and be administered: after adaptability feeds 3d, weighed weight, fasting 12h posterior orbit venous plexus is taken a blood sample, and measures
TC, TG level in serum, according to the horizontal random packet of TC, TG, often group 7, respectively organizes TC, TG base level zero difference.The most right
According to group, model control group, positive controls (Essentiale N/Essentiale Forte N 136.8mg/kg), Folium Nelumbinis group (600mg/kg), Folium Mori group (600mg/
Kg), lotus kind group (600mg/kg), Hawthorne group (600mg/kg) and Folium Nelumbinis compositions group (Folium Nelumbinis, Folium Mori and Folium Ipomoeae 8:1:1,
600mg/kg)；In addition to Normal group, remaining rat the most quantitatively gives high lipid food (by standard feed, Adeps Sus domestica, cholesterol, egg
Bloom, whole milk powder, cholate forms), continuous 16 weeks.The while of modeling, except Normal group and model control group gavage distilled water
Outward, remaining is respectively organized gavage respectively and gives corresponding dosage medicine, every day 1 time, and gavage volume is 1mL/100g weight, and continuous 16
Week.
2.2, Testing index
2.2.1, water 12h, 3% pentobarbital sodium lumbar injection fiber crops are can't help in Biochemistry test fasting after last is administered
Liquor-saturated rat, postcava is taken a blood sample, centrifugal, takes serum, full automatic biochemical apparatus detection serum TC, TG, HDL-C, ALT, AST, uric acid
(UA) and glucose (GLU) level, concrete operations reference reagent box description is carried out.
2.2.2, hepatic tissue sample preparation blood sampling after be rapidly separated liver, ice normal saline cleans bloodstain, takes right lobe of liver group
Knitting, neutral formalin is fixed, for liver histopathology inspection；Take same position hepatic tissue about 0.5g, add the 0.9% of pre-cooling
Normal saline 4.5mL, fully grinds at ice-water bath high speed disperser, and 3500rpm is centrifuged 10min, takes supernatant, is
10%, standby；ELISA method detection liver tissue homogenate's free fatty (FFA), low density lipoprotein receptor (LDL-R) level, tool
Gymnastics is made reference reagent box description and is carried out.
2.2.3, oil red O stain observe hepatocyte lipid Infiltrating blood sampling after be rapidly separated liver, ice normal saline is washed
Clean bloodstain, takes right lobe of liver same area hepatic tissue ,-80 DEG C of frosts, section, oil red O stain, observes each group of rat hepatocytes lipid
Infiltrating.
2.3, statistical procedures measurement data withRepresenting, comparing employing t inspection between two groups, P < 0.05 represents difference
Statistically significant.
3, result
3.1, to rat model blood fat, liver function index and serum uric acid, the effect of glucose level
Table 1-1 result shows, compares with Normal group, and model group rats serum TC, TG and hepatic tissue FFA level are notable
Raising (P < 0.01), hepatic tissue LDL-R level significantly reduces (P < 0.05), and Serum HDL-C has reduction trend, points out now model
There is disorders of lipid metabolism in rat and blood lipid level crosses high state；Comparing with model group, each tested material the most all can significantly reduce model
Serum TC, TG (P < 0.01) and hepatic tissue FFA level (P < 0.05), elevating HDL-C and hepatic tissue LDL-R level (P
< 0.05), wherein the effect of Folium Nelumbinis compositions is the strongest.Table 1-2 result shows, compares with Normal group, model group rats blood
Clear ALT, AST level significantly raises (P < 0.01), points out now rat model liver function to damage；Compare with model group, respectively
Tested material all can reduce rat model Serum ALT, AST level (P < 0.01 or P < 0.05), points out each tested material to have liver function
Certain protective effect.Table 1-3 result shows, compares with Normal group, rat model serum uric acid (UA) and glucose
(GLU) level significantly raises (P < 0.05), compares with model control group, and Hawthorne, lotus kind and Folium Nelumbinis compositions all can significantly reduce
Rat model serum UA and GLU level (P < 0.05), three's effect is the most obvious with Folium Nelumbinis compositions；Folium Nelumbinis and Folium Mori are alone right
UA and GLU raised all has certain reduction effect, and wherein Folium Nelumbinis reduces UA level more significantly (P < 0.05), the low GLU of Folium Mori
Level is more notable (P < 0.05).
Table 1-1: Folium Nelumbinis compositions is to rat model blood lipids index and the effect of hepatic tissue FFA, LDL-R level
Note: compare with Normal group,#P < 0.05,##P<0.01；Compare with model control group, * P≤0.05, * * P <
0.01；Lower same.
Table 1-2: the Folium Nelumbinis compositions impact on rat model liver function index
| Packet | ALT(U/L) | AST(U/L) |
| Normal group | 70.9±11.6 | 154.2±13.3 |
| Model control group | 99.3±15.1## | 207.5±22.7## |
| Essentiale N/Essentiale Forte N group | 75.3±7.2 | 167.2±33.2* |
| Folium Mori group | 82.2±7.3* | 163.2±29.5* |
| Folium Nelumbinis group | 76.2±12.7* | 180.4±30.5 |
| Lotus kind group | 73.8±7.6** | 176.8±12.4* |
| Hawthorne group | 76.8±9.8** | 165.8±15.3** |
| Folium Nelumbinis compositions group | 76.0±12.8* | 143.5±20.4** |
Table 1-3: Folium Nelumbinis compositions is on rat model serum uric acid and the impact of glucose level
| Packet | UA(μmol/L) | GLU(mmol/L) |
| Normal group | 50.6±6.6 | 5.8±0.9 |
| Model control group | 61.8±3.5# | 9.0±2.6# |
| Essentiale N/Essentiale Forte N group | 72.2±12.2 | 6.2±0.3* |
| Folium Mori group | 61.1±19.4 | 6.7±0.9* |
| Folium Nelumbinis group | 52.2±10.5* | 7.3±1.3 |
| Lotus kind group | 55.5±3.5* | 6.8±0.6* |
| Hawthorne group | 53.7±5.2* | 6.4±0.2* |
| Folium Nelumbinis compositions group | 47.3±13.3* | 6.3±1.0* |
3.2, to liver histopathology and the effect of hepatocyte lipidosis
Liver histopathology checks that result and oil red O stain result show, during normal rat hepatocyte with central vein is
The heart is arranged radially, and liver cell nuclear is big and justifies, and is positioned at the central authorities of cell, and nuclear membrane understands, chromatin is sparse；Rat model liver group
Knitting in white powder, cell rope arrangement disorder, karyopyknosis, lobules of liver fat becomes apparent, vesicle and Macrovesicular steatosis
Coexist, hepatocyte lipidosis substantially (in hepatocyte, the fat of deposition drips and taken on a red color by dye), and visible inflammatory cell infiltration and point
Shape necrosis region；Folium Nelumbinis and Folium Mori hepatic cords are arranged radially, and compare model control group rat, hepatocyte lipid infiltration degree
Reduce；Folium Nelumbinis compositions group rats'liver rope is clear, and hepatic sinusoid is slightly expanded, and hepatocyte fat becomes and inflammatory cell infiltration relatively model
Group significantly alleviates.The above results prompting Folium Nelumbinis compositions can effectively alleviate NAFLD rat hepatocytes lipidosis, improves hepatic tissue
Pathological change, effect is better than that Folium Nelumbinis, Folium Mori are alone and lotus kind, Hawthorne combination (see photo).
The studies above result shows, Folium Nelumbinis, Folium Mori, lotus kind, Hawthorne and Folium Nelumbinis compositions cause non-alcoholic to high fat diet
Fatty liver all has certain preventive and therapeutic effect, but each application point exists certain difference.Folium Mori to the effect of blood lipid metabolism to rise
High Serum HDL-C and hepatic LDL-receptor level, reduce liver free fatty (FFA) more obvious, the most also has significantly fall
Blood glucose effect；Folium Nelumbinis is more notable to reduce TC, TG and uric acid level, and it is obvious that its effect raising HDL-C level is not so good as Folium Mori；
NAFLD effect is compared alone Folium Nelumbinis, Folium Mori and lotus kind, Hawthorne combination relatively comprehensively by Folium Nelumbinis compositions, to blood lipid level
And serum uric acid and glucose level have a good regulation effect, and antagonism liver lipidosis and liver function protecting effect side
Face, will be substantially better than alone and lotus kind, Hawthorne combination.To sum up illustrating, this Folium Nelumbinis compositions combines the effect of Folium Mori, Folium Nelumbinis,
5 with after Folium Ipomoeae, and the effect of its preventing and treating NAFLD is more comprehensively and significantly.
Embodiment 2: Folium Nelumbinis compositions causes the Effect study of hyperlipemia to high lipid food
1, experiment material
1.1, Animals Male SD rat, body weight 200 ± 20g, purchased from Zhejiang Academy of Medical Sciences Experimental Animal Center (animal
The certification of fitness number: 0008677, credit number: SCXK (Zhejiang) 2008-0033).In room temperature 23 ± 2 DEG C, relative humidity 50%-
70% raises, and free diet is drunk water.
1.2, tested material: the lyophilization to pulverize the Folium Nelumbinis of 800-1000 mesh sieve, powder of Folium Mori appropriate of learning from else's experience, adds pure respectively
Water is configured to suspension, obtains Folium Nelumbinis tested material and Folium Mori tested material；Separately take Folium Nelumbinis, Folium Ipomoeae and Folium Nelumbinis, Mulberry respectively in 8:2 ratio
Leaf, mixing, add pure water and be configured to suspension, obtain lotus kind tested material and Hawthorne tested material；Take Folium Nelumbinis, Folium Mori and Folium Ipomoeae powder by 8:
1:1 mixes, and adds pure water and is configured to suspension, obtains Folium Nelumbinis compositions tested material.
2, experimental technique
2.1, it is grouped and is administered rat adaptability is fed after 7d, weighed weight, it is randomly divided into Normal group and makes
Module, in addition to rats in normal control group, remaining rat gives high lipid food, fasting 12h posterior orbit venous plexus blood sampling after 2 weeks, surveys
Determine TC level in serum, be randomly divided into 7 groups according to TC level: (atropic cuts down for Normal group, model control group, positive controls
Statin 6.0mg/kg), alone group of Folium Nelumbinis (0.6g/kg), alone group of Folium Mori (0.6g/kg), Folium Nelumbinis compositions group (0.6g/kg),
Often group 7.All rats all give high-sugar-fat-diet, and continuous 5 weeks, free choice feeding was drunk water.From modeling the l days, except normal
Matched group and model control group gavage outside distilled water, and remaining each administration group gavage respectively gives the tested material of corresponding dosage, every day 1
Secondary, gavage volume is 1ml/100g weight, continuous 4 weeks.
2.2, blood biochemical analysis Indexs measure is administered 2,4 weeks, blood sampling, separates serum, and automatic clinical chemistry analyzer detection is big
Mus serum lipids biochemical indicator (TC, TG, LDL-C, HDL-C), liver function biochemical indicator (AST, ALT).
2.3, Lee, s index and fat index measure dosage period end, weighed rat weight, measure rat body long, and
Calculate Lee, s index.Lee, s index=weight (g) 1/3 × 103/ body is long.Dissect rat, cut open rapidly from body fat tissue
(genitals's peripheral adipose tissue, double perinephric fat tissue and groin fatty tissue), calculating fat index: fat index
=fat gross weight/weight × 100%.
2.4, statistical method measurement data data withRepresent, compare between normal control and model comparison two groups and adopt
With comparing employing one factor analysis of variance multiple comparisons between t-test, model group and each administration group, P ＜ 0.05 represents that difference has system
Meaning learned by meter.
3, result
Table 2-1,2-2 result shows, is administered the 2nd, 4 weeks, Folium Nelumbinis compositions can significantly reduce rat model serum TC, TG,
LDL-C level (P ＜ 0.01, P ＜ 0.05), wherein the effect with fall TC is more obvious, and effect is better than Folium Nelumbinis or Folium Mori are alone；
Meanwhile, Folium Nelumbinis compositions can also effectively raise HDL-C level；The above results display Folium Nelumbinis compositions fat to hyperlipemia disorder
Matter level has more preferable regulation effect.Table 2-3 result shows, modeling the 6th week (being administered the 4th week), rat model Serum ALT,
AST level significantly rises (P ＜ 0.01, P ＜ 0.05), points out now liver existing a certain degree of damage；With model control group
Ratio, Folium Mori are alone and lotus kind group rat blood serum ALT, AST level has downward trend, but there was no significant difference between each group；Folium Nelumbinis list
Within 4th week, rat model AST level can be significantly reduced by, Hawthorne and Folium Nelumbinis compositions being administered, wherein act on Folium Nelumbinis compositions
The most notable.Table 2-4 result shows, each tested material all can reduce rat model body weight, Lee's index and fat in various degree and refer to
Number (P ＜ 0.01), wherein the effect of Folium Nelumbinis compositions reduction Lee's index and fat index is better than other tested material groups.Lee, s
Index is the availability indexes in terms of evaluation adult rat obese degree, by rat Lee, s index and the index such as body weight, fat index
Synchro measure, can more fully evaluate fat-reducing drug effect.Table 2-4 result is pointed out, and Folium Nelumbinis compositions still has certain antiobesity action,
And effect is better than Folium Mori and Folium Nelumbinis is alone.
Table 2-1: on Hyperlipemia model rat serum TC, the impact of TG level
Note: compare with Normal group,△P < 0.05,△△P<0.01；Compare with model control group,*P < 0.05,**P<
0.01；Lower same.
Table 2-2: on Hyperlipemia model rat serum LDL-C, the impact of HDL-C level
Table 2-3: on Hyperlipemia model rat Serum ALT, the impact of AST level
Table 2-4: on Hyperlipemia model rat Lee's index and the impact of fat index
| Packet | Dosage (g/kg) | Body weight (g) | Lee's index | Fat index (%) |
| Normal group | - | 226.0±11.8 | 293.2±9.0 | 1.09±0.19 |
| Model group | - | 232.5±11.4 | 307.0±10.2△ | 1.33±0.12△ |
| Atorvastatin group | 6×10-3 | 221.3±7.9* | 299.4±5.9 | 0.97±0.17** |
| Folium Nelumbinis group | 0.6 | 210.8±6.1** | 290.9±11.8* | 0.99±0.42 |
| Folium Mori group | 0.6 | 218.8±20.9 | 292.8±7.8* | 1.05±0.49 |
| Lotus kind group | 0.6 | 221.5±9.0* | 297.5±5.1* | 0.98±0.29* |
| Hawthorne group | 0.6 | 217.2±4.8* | 291.4±4.3** | 0.98±0.27* |
| Folium Nelumbinis compositions group | 0.6 | 218.8±3.4* | 289.0±1.5** | 0.82±0.31** |
Embodiment 3: experimental non-alcoholic fatty liver disease liver fat is become and the effect of insulin resistant by different components
Chinese herbal medicines/the bread and cheeses such as Folium Nelumbinis, Folium Mori, Folium Camelliae sinensis, Folium Ipomoeae are combined by the present invention, and observe
Each compositions causes nonalcoholic fatty liver model Liver Function, liver index, hepatic steatosis and insulin to high glucose and high fat and is correlated with
The effect of index.Table 3-1 result shows, Folium Nelumbinis compositions group (Folium Nelumbinis Folium Mori Folium Ipomoeae 81 1) is to laboratory non-alcoholic
Fatty liver has good preventive and therapeutic effect, is better than other combinations in terms of anti-hepatocyte fat becomes and improves Insulin Resistance
Thing.Experimental rats with nonalcoholic fatty liver disease liver function index, liver fat are become and insulin resistant phase by table 3-1: different components
Close the effect of index
Note: A group: Normal group；B group: model control group；C group: Essentiale N/Essentiale Forte N matched group；D group: lotus tea group (Folium Nelumbinis powder
Green tea powder 8 2)；E group: Hawthorne tea group (Folium Nelumbinis powder powder of Folium Mori Folium Camelliae sinensis powder 81 1)；F group: Hawthorne tea kind group (Folium Nelumbinis powder Folium Mori
Powder Folium Camelliae sinensis powder Folium Ipomoeae powder 711 1)；G group: Folium Nelumbinis compositions group (Folium Nelumbinis Folium Mori Folium Ipomoeae 81 1)；H group: mulberry leaf tea kind
Group (powder of Folium Mori Folium Camelliae sinensis powder Folium Ipomoeae powder 72 1).
Embodiment 4: different ratio Folium Nelumbinis compositions is to nonalcoholic fatty liver model rat fat and the work of liver lipid level
With
The present invention causes nonalcoholic fatty liver model rat fat and liver to different ratio Folium Nelumbinis compositions to high glucose and high fat
The effect of lipid level is observed.Table 4-1 result shows, each proportioning Folium Nelumbinis compositions is to experimental non-alcoholic fatty liver disease mould
Type Serum TC, LDL-C and hepatic tissue TC, TG level are respectively provided with reduction effect；Above-mentioned effect is increased along with Folium Nelumbinis ratio
And strengthen.Therefore the optimum combination that Folium Nelumbinis compositions 5 groups (H group, Folium Nelumbinis Folium Mori Folium Ipomoeae 81 1) is the present invention.
Table 4-1: different ratio Folium Nelumbinis compositions is to nonalcoholic fatty liver model rat fat and the effect of liver lipid level
Note: A group: Normal group；B group: model control group；C group: Essentiale N/Essentiale Forte N matched group；D group: Folium Nelumbinis compositions 1 group
(Folium Nelumbinis Folium Mori Folium Ipomoeae 53 2)；E group: Folium Nelumbinis compositions 2 groups (Folium Nelumbinis Folium Mori Folium Ipomoeae 62 2)；F group: Folium Nelumbinis combines
Thing 3 groups (Folium Nelumbinis Folium Mori Folium Ipomoeae 71 2)；G group: Folium Nelumbinis compositions 4 groups (Folium Nelumbinis Folium Mori Folium Ipomoeae 72 1)；H group: lotus
Leaf composition 5 groups (Folium Nelumbinis Folium Mori Folium Ipomoeae 81 1).
Accompanying drawing 1 shows that (HE contaminates to the effect of NAFLD liver tissues of rats pathological change for Folium Nelumbinis, Folium Mori and Folium Nelumbinis compositions
Color, 400 ×).Rat model hepatocyte Macrovesicular steatosis, karyopyknosis or disappearance, inflammatory cell infiltration substantially (↑)；Lotus
Leaf composition can be effectively improved rat model hepatic tissue pathology and change.
Accompanying drawing 2 shows Folium Nelumbinis, Folium Mori and Folium Nelumbinis compositions effect (the oil red O to NAFLD rat hepatocytes lipidosis
Dyeing, 200 ×).Substantially (the red dye ↑ of lipid), Folium Nelumbinis compositions can significantly alleviate lipid and sink rat model hepatocyte lipidosis
Long-pending degree, effect is better than Folium Nelumbinis and Folium Mori are alone and Folium Nelumbinis-Folium Ipomoeae, Folium Nelumbinis-Folium Mori combination.
Above-described is only the preferred embodiment of the present invention, it is noted that for common skill in the art
For art personnel, on the premise of without departing from core technical features of the present invention, it is also possible to make some improvement, these improve and profit
Decorations also should be regarded as protection scope of the present invention.
Claims (4)
1. a Folium Nelumbinis compositions, it is characterised in that it comprises Folium Nelumbinis powder, powder of Folium Mori, Folium Ipomoeae powder etc., described Folium Nelumbinis powder, Mulberry
Ye Fen, Folium Ipomoeae powder cross 800-1500 mesh sieve, by quality proportioning 8-1: 1-8: 1-8 mixing.
Folium Nelumbinis compositions the most according to claim 1, it is characterised in that described Folium Nelumbinis powder, powder of Folium Mori, the quality of Folium Ipomoeae powder
Proportioning is preferably 8: 1: 1.
3. Folium Nelumbinis compositions described in a claim 1 regulates blood fat and prevention in preparation, improves and treat non-alcoholic fatty
Application in the food of liver, health food and medicine.
Application the most according to claim 3, it is characterised in that described Folium Nelumbinis compositions is at food, health food and medicine
In mass content be about 1-100%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610611570.3A CN106213500A (en) | 2016-07-29 | 2016-07-29 | A kind of Folium Nelumbinis compositions and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610611570.3A CN106213500A (en) | 2016-07-29 | 2016-07-29 | A kind of Folium Nelumbinis compositions and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106213500A true CN106213500A (en) | 2016-12-14 |
Family
ID=57536176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610611570.3A Pending CN106213500A (en) | 2016-07-29 | 2016-07-29 | A kind of Folium Nelumbinis compositions and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106213500A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108669256A (en) * | 2018-04-03 | 2018-10-19 | 徐州工程学院 | A kind of ginkgo leaf health care tea and preparation method thereof |
| CN108850369A (en) * | 2018-08-29 | 2018-11-23 | 贾炎龙 | A kind of preparation method of hypoglycemic tea |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103283890A (en) * | 2013-06-19 | 2013-09-11 | 山东华夏茶联茶业有限公司 | Health-care dark tea |
| CN103933379A (en) * | 2014-03-17 | 2014-07-23 | 戴明传 | Eight-element anti-diabetes powder |
| CN105105008A (en) * | 2015-10-16 | 2015-12-02 | 马平 | Diet noodles with weight losing function and preparation method thereof |
-
2016
- 2016-07-29 CN CN201610611570.3A patent/CN106213500A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103283890A (en) * | 2013-06-19 | 2013-09-11 | 山东华夏茶联茶业有限公司 | Health-care dark tea |
| CN103933379A (en) * | 2014-03-17 | 2014-07-23 | 戴明传 | Eight-element anti-diabetes powder |
| CN105105008A (en) * | 2015-10-16 | 2015-12-02 | 马平 | Diet noodles with weight losing function and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈广垠: "《图解中草药》", 30 June 2014, 新疆人民卫生出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108669256A (en) * | 2018-04-03 | 2018-10-19 | 徐州工程学院 | A kind of ginkgo leaf health care tea and preparation method thereof |
| CN108850369A (en) * | 2018-08-29 | 2018-11-23 | 贾炎龙 | A kind of preparation method of hypoglycemic tea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hopkins et al. | Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies | |
| US9439937B2 (en) | Rat-eye bean extract improving blood glucose control and bioactivity and method of producing the same | |
| JPWO2005074960A1 (en) | Functional beverages and compositions | |
| CN103027155A (en) | Mulberry leaf lipid-reducing pressure-reducing health-care tea and preparation method thereof | |
| CN104383156B (en) | A kind of composition with weight-reducing and blood fat reducing function and preparation method thereof and purposes | |
| CN107951935A (en) | A kind of pueraria lobata hoveniae semoveniae semen broken wall composition and its preparation method and application | |
| CN104286297A (en) | Preparation method of substitute tea-black soya bean tea | |
| CN102423374A (en) | Pharmaceutical composition with antiobesity action | |
| CN101999652B (en) | Blood fat-reducing health-care food and preparation method thereof | |
| CN106213500A (en) | A kind of Folium Nelumbinis compositions and application thereof | |
| CN104286269B (en) | A kind of Qingqian Willow leaf bealth-care instant tea and preparation method thereof | |
| CN105596576A (en) | Tea bag with blood fat reducing action | |
| CN101283781A (en) | Rose tricholoma matsutake edible stuffing | |
| CN103230486B (en) | Traditional Chinese medicine composition, preparation method thereof, and application thereof in preparing medicines used for treating fatty liver | |
| CN102258192B (en) | Enhanced red date soft capsule nutrition | |
| CN101637212A (en) | Chewing gum having effects of preventing and treating high blood pressure | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| KR101690369B1 (en) | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof | |
| KR100908449B1 (en) | Functional Cheonggukjang Drink with Thrombus Solubility | |
| KR20160014075A (en) | Cynanchi Wilfordii Tea and Manufacture Method thereof | |
| CN115444922A (en) | Anti-fatigue medicinal and edible composition and application thereof | |
| CN104474337B (en) | A kind of preparation method containing in green-tea extract into health instant powder | |
| CN107873900A (en) | A kind of instant Pu'er tea and preparation method thereof | |
| KR101383960B1 (en) | Development of functional food for weight regulation through activation ampk and inhibition lipid absorption in intestine using extract of unripe astringent persimmon | |
| CN106072099A (en) | A kind of health food of auxiliary reducing blood lipid containing green plum and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |
|
| RJ01 | Rejection of invention patent application after publication |